The research progress of hyperprolactinemia_West China Medical Journal

Authors：

 YANG Jing , CUI Junfang , LAN Lizhen

Department of Endocrine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P. R. China;

Corresponding author：

YANG Jing, Email: yangjlm@126.com

Keywords：

Hyperprolactinemia; Treatment; Drug resistance; Prolactinoma

DOI：

10.7507/1002-0179.201804043

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Hyperprolactinemia is the common clinical syndrome; the causes of hyperprolactinemia are physiological, pharmacological, and pathological, in which prolactinoma is the most common cause. In drug therapy, dopamine agonists are the first choice, but there are 10%–20% of the patients who are resistant to drug therapy. This paper mainly summarized the causes, treatments, mechanisms of drug resistance, treatment during pregnancy, and progresses in the treatment of prolactinoma, so as to provide some theoretical basis to further research of hyperprolactinemia.

Citation： YANG Jing, CUI Junfang, LAN Lizhen. The research progress of hyperprolactinemia. West China Medical Journal, 2018, 33(5): 509-512. doi: 10.7507/1002-0179.201804043 Copy

1.	中华医学会妇产科学分会内分泌学组. 女性高催乳素血症诊治共识. 中华妇产科杂志, 2016, 51(3): 161-168.
2.	中华医学会神经外科学分会, 中华医学会妇产科学分会, 中华医学会内分泌学分会. 高催乳素血症诊疗共识. 中华医学杂志, 2011, 91(3): 147-154.
3.	Capozzi A, Scambia G, Pontecorvi A, et al. Hyperprolactinemia: pathophysiology and therapeutic approach. Gynecol Endocrinol, 2015, 31(7): 506-510.
4.	Paepegaey AC, Salenave S, Kamenicky P, et al. Cabergoline tapering is almost always successful in patiets with macroprolactinomas. J Endocr Soc, 2017, 1(3): 221-230.
5.	Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol metab, 2011, 96(2): 273-288.
6.	Li Z, Liu Q, Li C, et al. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas. Mol Cell Endocrinol, 2015, 402: 64-71.
7.	王友伟, 马驰原. 多巴胺受体激动剂治疗泌乳素瘤的机制及研究进展. 中华神经外科疾病研究杂志, 2013, 12(3): 286-288.
8.	Xia J, Wishart DS. Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst. Nat Protoc, 2011, 6(6): 743-760.
9.	Tamada M, Nagano O, Tateyama S, et al. Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. Cancer Res, 2012, 72(6): 1438-1448.
10.	Grabellus F, Sheu SY, Tötsch M, et al. Overexpression of the drug resistance-associated protein metallothionein does not correlate with response of sarcomas to isolated limb perfusion treatment. J Surg Oncol, 2010, 101(6): 465-470.
11.	Zang Q, Liu Y, He J, et al. A sensitive and rapid HPLC-MS/MS method for the quantitative determination of trace amount of bromocriptine in small clinical prolactinoma tissue. J Chromatogr B Analyt Technol Biomed Life Sci, 2015, 989: 91-97.
12.	Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 2005, 120(1): 15-20.
13.	Wu ZB, Li WQ, Lin SJ, et al. MicroRNA expression profile of bromocriptine-resistant prolactinomas. Mol Cell Endocrinol, 2014, 395(1/2): 10-18.
14.	Di Zazzo E, De Rosa C, Abbondanza C, et al. PRDM proteins: molecular mechanisms in signal transduction and transcriptional regulation. Biology (Basel), 2013, 2(1): 107-141.
15.	Gao H, Wang F, Lan X, et al. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas. BMC Cancer, 2015, 15: 272.
16.	Almalki MH, Aljoaib NN, Alotaibi MJ, et al. Temozolmide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review. Hormones (Athens), 2017, 16(2): 139-149.

1. 中华医学会妇产科学分会内分泌学组. 女性高催乳素血症诊治共识. 中华妇产科杂志, 2016, 51(3): 161-168.
2. 中华医学会神经外科学分会, 中华医学会妇产科学分会, 中华医学会内分泌学分会. 高催乳素血症诊疗共识. 中华医学杂志, 2011, 91(3): 147-154.
3. Capozzi A, Scambia G, Pontecorvi A, et al. Hyperprolactinemia: pathophysiology and therapeutic approach. Gynecol Endocrinol, 2015, 31(7): 506-510.
4. Paepegaey AC, Salenave S, Kamenicky P, et al. Cabergoline tapering is almost always successful in patiets with macroprolactinomas. J Endocr Soc, 2017, 1(3): 221-230.
5. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol metab, 2011, 96(2): 273-288.
6. Li Z, Liu Q, Li C, et al. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas. Mol Cell Endocrinol, 2015, 402: 64-71.
7. 王友伟, 马驰原. 多巴胺受体激动剂治疗泌乳素瘤的机制及研究进展. 中华神经外科疾病研究杂志, 2013, 12(3): 286-288.
8. Xia J, Wishart DS. Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst. Nat Protoc, 2011, 6(6): 743-760.
9. Tamada M, Nagano O, Tateyama S, et al. Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. Cancer Res, 2012, 72(6): 1438-1448.
10. Grabellus F, Sheu SY, Tötsch M, et al. Overexpression of the drug resistance-associated protein metallothionein does not correlate with response of sarcomas to isolated limb perfusion treatment. J Surg Oncol, 2010, 101(6): 465-470.
11. Zang Q, Liu Y, He J, et al. A sensitive and rapid HPLC-MS/MS method for the quantitative determination of trace amount of bromocriptine in small clinical prolactinoma tissue. J Chromatogr B Analyt Technol Biomed Life Sci, 2015, 989: 91-97.
12. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 2005, 120(1): 15-20.
13. Wu ZB, Li WQ, Lin SJ, et al. MicroRNA expression profile of bromocriptine-resistant prolactinomas. Mol Cell Endocrinol, 2014, 395(1/2): 10-18.
14. Di Zazzo E, De Rosa C, Abbondanza C, et al. PRDM proteins: molecular mechanisms in signal transduction and transcriptional regulation. Biology (Basel), 2013, 2(1): 107-141.
15. Gao H, Wang F, Lan X, et al. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas. BMC Cancer, 2015, 15: 272.
16. Almalki MH, Aljoaib NN, Alotaibi MJ, et al. Temozolmide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review. Hormones (Athens), 2017, 16(2): 139-149.

Previous Article
The relationship between obesity and thyroid function
Next Article
Interpretation of American Diabetes Association Standards of Medical Care in Diabetes-2018

West China Medical Journal

The research progress of hyperprolactinemia

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content